follow releas preliminari result lower
number reflect assumpt disrupt major segment bsx
busi medic devic industri continu appreci driver longer-
term organ revenu growth assum quarterli revenu declin throughout
recoveri revis pt
heavili expos global elect procedur shutdown recoveri outlook
drive share
announc result april manag issu guidanc
time compani report januari project organ sale growth
guidanc includ neg impact
reflect slowdown china procedur volum disrupt suppli chain sinc
outbreak spread europ creat stronger-
than-anticip headwind earlier month pre-announce organ constant
currenc revenu declin approxim flat slight growth report
basi impli shortfal histor revenu estim new
revenu estim bottom line compani initi ep guidanc rang
impli growth approxim midpoint although
yet know success reduc variabl cog sg expens
compani provid preliminari ep estim forecast gm om
contract respect revis ep forecast
withdrew guidanc restart elect procedur crucial
pull full-year guidanc due uncertainti tie
previou guidanc call organ sale growth om expans bp
ep growth tabl time revers
execut order recommend shut elect procedur govern
medic societi like initi crucial catalyst recoveri path
bsx busi unit check suggest compani devic franchis
highli lever elect procedur current think impact elect
case strongest soften gradual remaind
anticip recoveri organ revenu growth om expans ep growth
return new estim revenu om
bp contract ep prove conserv elect procedur
open back earlier expect
multipl driver readi recoveri
continu appreci potenti bsx product portfolio deliv top-tier
organ revenu growth recoveri era notabl item includ exalt-
endo strong structur heart contribut lotu accur watchman
sentinel btg integr expect product approv like ranger dcb
sfa use new product launch ep directsens cathet
rhytmia hdx polarx cryo acceler urology/pelv
lithovu spaceoar rexm due multipl contract med tech space
revis out-year estim revis price target time updat
ep forecast previous nonetheless bsx recoveri
trajectori remain one attract large-cap coverag univers
pleas see page report import disclosur
one three cardio rhythm manag space
seen sign stabil past sever quarter return single-digit
constant currenc top-lin growth accompani margin expans initi
stabil market robust pipelin product meaning contribut
revenu factor increas convict compani continu
outperform large-cap med devic peer
on-going limit eu launch lotu
on-going us roll-out lotu
fda follow-up june fda panel
meet safeti paclitaxel
devic pad
maintain market share
mri-saf pacemak
driven mri-saf approv
drive continu share gain face
structur heart driver tavr
top-lin growth exceed high
end long-term guidanc
market share loss
de market continu declin along
synergi share loss
weaker lotu watchman
global medic devic compani offer product
cardiovascular peripher intervent electrophysiolog endoscopi urology/
women health neuromodul busi unit compani vast product portfolio
pipelin allow expand new adjac market asthma atrial
fibril hypertens tavr parkinson diseas variou strategi initi
play continu mid-single-digit revenu growth bsx main competitor
busi abbott
compani report thomson eikon cowen compani
incom statement mm except per share good incom total interest pre-tax tax net incom ep net ep share cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
continu util pressur competit dynam global potenti
regulatori delay reject failur devic clinic trial lotu valv vessix
and/or weaken demand develop market econom and/or polit uncertainti
emerg market post acquisit integr issu bard electrophysiolog
busi orbu neich win perman injunct germani versu de
technolog platform stj durata lead recal lead full stabil recoveri
busi fluctuat foreign exchang rate
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock corp corp secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
